<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33264630</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>9</Issue><PubDate><Year>2020</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Rare Variant Burden Analysis within Enhancers Identifies CAV1 as an ALS Risk Gene.</ArticleTitle><Pagination><StartPage>108456</StartPage><MedlinePgn>108456</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">108456</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2020.108456</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(20)31445-5</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disease. CAV1 and CAV2 organize membrane lipid rafts (MLRs) important for cell signaling and neuronal survival, and overexpression of CAV1 ameliorates ALS phenotypes in&#xa0;vivo. Genome-wide association studies localize a large proportion of ALS risk variants within the non-coding genome, but further characterization has been limited by lack of&#xa0;appropriate tools. By designing and applying a pipeline to identify pathogenic genetic variation within enhancer elements responsible for regulating gene expression, we identify disease-associated variation within CAV1/CAV2 enhancers, which replicate in an independent cohort. Discovered enhancer mutations reduce CAV1/CAV2 expression and disrupt MLRs in patient-derived cells, and CRISPR-Cas9 perturbation proximate to a patient mutation is sufficient to reduce CAV1/CAV2 expression in neurons. Additional enrichment of ALS-associated mutations within CAV1 exons positions CAV1 as an ALS risk gene. We propose CAV1/CAV2 overexpression as a personalized medicine target for ALS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cooper-Knock</LastName><ForeName>Johnathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK. Electronic address: j.cooper-knock@sheffield.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Sai</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Stanford Center for Genomics and Personalized Medicine, Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kenna</LastName><ForeName>Kevin P</ForeName><Initials>KP</Initials><AffiliationInfo><Affiliation>Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moll</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franklin</LastName><ForeName>John P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>Samantha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nezhad</LastName><ForeName>Helia Ghahremani</ForeName><Initials>HG</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iacoangeli</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yacovzada</LastName><ForeName>Nancy Y</ForeName><Initials>NY</Initials><AffiliationInfo><Affiliation>Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eitan</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hornstein</LastName><ForeName>Eran</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elhaik</LastName><ForeName>Eran</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Biology, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Celadova</LastName><ForeName>Petra</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Nucleic Acids, University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bose</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Nucleic Acids, University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farhan</LastName><ForeName>Sali</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fishilevich</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lancet</LastName><ForeName>Doron</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morrison</LastName><ForeName>Karen E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Southampton, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Christopher E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Project MinE ALS Sequencing Consortium</CollectiveName></Author><Author ValidYN="Y"><LastName>Veldink</LastName><ForeName>Jan H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirby</LastName><ForeName>Janine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snyder</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Stanford Center for Genomics and Personalized Medicine, Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK. Electronic address: pamela.shaw@sheffield.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>216596/Z/19/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L501529/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R56 NS073873</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS073873</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ALCHALABI-DOBSON/APR14/829-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>213501/Z/18/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0600974</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/R024804/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495540">CAV1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051242">Caveolin 1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Cell Rep. 2021 Feb 2;34(5):108730</RefSource><PMID Version="1">33535055</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051242" MajorTopicYN="N">Caveolin 1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016678" MajorTopicYN="N">Genome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CAV1</Keyword><Keyword MajorTopicYN="N">CAV2</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">gene enhancers</Keyword><Keyword MajorTopicYN="N">membrane lipid rafts</Keyword><Keyword MajorTopicYN="N">non-coding DNA</Keyword><Keyword MajorTopicYN="N">whole-genome sequencing</Keyword></KeywordList><CoiStatement>Declaration of Interests The authors declare no competing interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Blair</LastName><ForeName>Ian</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wray</LastName><ForeName>Naomi</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kiernan</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neto</LastName><ForeName>Miguel Mitne</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chio</LastName><ForeName>Adriano</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cauchi</LastName><ForeName>Ruben</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robberecht</LastName><ForeName>Wim</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Damme</LastName><ForeName>Philip</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Corcia</LastName><ForeName>Phillippe</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Couratier</LastName><ForeName>Phillipe</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hardiman</LastName><ForeName>Orla</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>McLaughlin</LastName><ForeName>Russel</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gotkine</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Drory</LastName><ForeName>Vivan</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ticozzi</LastName><ForeName>Nicola</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silani</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Veldink</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Leonard</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Carvalho</LastName><ForeName>Mamede</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pardina</LastName><ForeName>Jesus Mora</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Povedano</LastName><ForeName>Monica</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andersen</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wber</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ba&#x15f;ak</LastName><ForeName>Nazli</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Pamela</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morrison</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Landers</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glass</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>2</Day><Hour>20</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33264630</ArticleId><ArticleId IdType="pmc">PMC7710676</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2020.108456</ArticleId><ArticleId IdType="pii">S2211-1247(20)31445-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Al-Chalabi A., Calvo A., Chio A., Colville S., Ellis C.M., Hardiman O., Heverin M., Howard R.S., Huisman M.H.B., Keren N. Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol. 2014;13:1108&#x2013;1113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4197338</ArticleId><ArticleId IdType="pubmed">25300936</ArticleId></ArticleIdList></Reference><Reference><Citation>Aman A.T., Fraser S., Merritt E.A., Rodigherio C., Kenny M., Ahn M., Hol W.G.J., Williams N.A., Lencer W.I., Hirst T.R. A mutant cholera toxin B subunit that binds GM1- ganglioside but lacks immunomodulatory or toxic activity. Proc. Natl. Acad. Sci. USA. 2001;98:8536&#x2013;8541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC37471</ArticleId><ArticleId IdType="pubmed">11447291</ArticleId></ArticleIdList></Reference><Reference><Citation>Arganda-Carreras I., Fern&#xe1;ndez-Gonz&#xe1;lez R., Mu&#xf1;oz-Barrutia A., Ortiz-De-Solorzano C. 3D reconstruction of histological sections: Application to mammary gland tissue. Microsc. Res. Tech. 2010;73:1019&#x2013;1029.</Citation><ArticleIdList><ArticleId IdType="pubmed">20232465</ArticleId></ArticleIdList></Reference><Reference><Citation>Basu S., Pan W. Comparison of statistical tests for disease association with rare variants. Genet. Epidemiol. 2011;35:606&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3197766</ArticleId><ArticleId IdType="pubmed">21769936</ArticleId></ArticleIdList></Reference><Reference><Citation>Bemelmans A.-P., Husson I., Jaquet M., Mallet J., Kosofsky B.E., Gressens P. Lentiviral-mediated gene transfer of brain-derived neurotrophic factor is neuroprotective in a mouse model of neonatal excitotoxic challenge. J. Neurosci Res. 2006;83:50&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">16299771</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry J.D., Cudkowicz M.E., Windebank A.J., Staff N.P., Owegi M., Nicholson K., McKenna-Yasek D., Levy Y.S., Abramov N., Kaspi H. NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker results. Neurology. 2019;93:e2294&#x2013;e2305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6937497</ArticleId><ArticleId IdType="pubmed">31740545</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B.R. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial &#x201c;Clinical limits of amyotrophic lateral sclerosis&#x201d; workshop contributors. J.&#xa0;Neurol. Sci. 1994;124(Suppl):96&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">7807156</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C.C., Chow C.C., Tellier L.C., Vattikuti S., Purcell S.M., Lee J.J. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4:7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4342193</ArticleId><ArticleId IdType="pubmed">25722852</ArticleId></ArticleIdList></Reference><Reference><Citation>Cingolani P., Platts A., Wang L.L., Coon M., Nguyen T., Wang L., Land S.J., Lu X., Ruden D.M. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 2012;6:80&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3679285</ArticleId><ArticleId IdType="pubmed">22728672</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli E.T., Goldstein D.B. Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat. Rev. Genet. 2010;11:415&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">20479773</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J., Jenkins T., Shaw P.J. Biota Publishing; 2013. Clinical and Molecular Aspects of Motor Neuron Disease.</Citation></Reference><Reference><Citation>Danecek P., Auton A., Abecasis G., Albers C.A., Banks E., DePristo M.A., Handsaker R.E., Lunter G., Marth G.T., Sherry S.T., 1000 Genomes Project Analysis Group The variant call format and VCFtools. Bioinformatics. 2011;27:2156&#x2013;2158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3137218</ArticleId><ArticleId IdType="pubmed">21653522</ArticleId></ArticleIdList></Reference><Reference><Citation>Day C.A., Kenworthy A.K. Functions of cholera toxin B-subunit as a raft cross-linker. Essays Biochem. 2015;57:135&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4346142</ArticleId><ArticleId IdType="pubmed">25658350</ArticleId></ArticleIdList></Reference><Reference><Citation>de Almeida C.J.G. Caveolin-1 and Caveolin-2 can be antagonistic partners in inflammation and beyond. Front. Immunol. 2017;8:1530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5715436</ArticleId><ArticleId IdType="pubmed">29250058</ArticleId></ArticleIdList></Reference><Reference><Citation>Drab M., Verkade P., Elger M., Kasper M., Lohn M., Lauterbach B., Menne J., Lindschau C., Mende F., Luft F.C. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science. 2001;293:2449&#x2013;2452.</Citation><ArticleIdList><ArticleId IdType="pubmed">11498544</ArticleId></ArticleIdList></Reference><Reference><Citation>Fishilevich S., Nudel R., Rappaport N., Hadar R., Plaschkes I., Iny Stein T., Rosen N., Kohn A., Twik M., Safran M. GeneHancer: genome-wide integration of enhancers and target genes in GeneCards. Database (Oxford) 2017;2017:bax028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5467550</ArticleId><ArticleId IdType="pubmed">28605766</ArticleId></ArticleIdList></Reference><Reference><Citation>Forster J.I., K&#xf6;glsberger S., Trefois C., Boyd O., Baumuratov A.S., Buck L., Balling R., Antony P.M.A. Characterization of Differentiated SH-SY5Y as Neuronal Screening Model Reveals Increased Oxidative Vulnerability. J. Biomol Screen. 2016;21:496&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4904349</ArticleId><ArticleId IdType="pubmed">26738520</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A., Wieland T., Richter B., Ruf W., Schaeffer V., M&#xfc;ller K., Marroquin N., Nordin F., H&#xfc;bers A., Weydt P. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat. Neurosci. 2015;18:631&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">25803835</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaj T., Ojala D.S., Ekman F.K., Byrne L.C., Limsirichai P., Schaffer D.V. In&#xa0;vivo genome editing improves motor function and extends survival in a mouse model of ALS. Sci. Adv. 2017;3:eaar3952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5738228</ArticleId><ArticleId IdType="pubmed">29279867</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasperini M., Tome J.M., Shendure J. Towards a comprehensive catalogue of validated and target-linked human enhancers. Nat. Rev. Genet. 2020;21:292&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7845138</ArticleId><ArticleId IdType="pubmed">31988385</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghavami S., Shojaei S., Yeganeh B., Ande S.R., Jangamreddy J.R., Mehrpour M., Christoffersson J., Chaabane W., Moghadam A.R., Kashani H.H. Autophagy and apoptosis dysfunction in neurodegenerative disorders. Prog. Neurobiol. 2014;112:24&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">24211851</ArticleId></ArticleIdList></Reference><Reference><Citation>Graur D. An upper limit on the functional fraction of the human genome. Genome Biol. Evol. 2017;9:1880&#x2013;1885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5570035</ArticleId><ArticleId IdType="pubmed">28854598</ArticleId></ArticleIdList></Reference><Reference><Citation>Head B.P., Peart J.N., Panneerselvam M., Yokoyama T., Pearn M.L., Niesman I.R., Bonds J.A., Schilling J.M., Miyanohara A., Headrick J. Loss of caveolin-1 accelerates neurodegeneration and aging. PLoS ONE. 2010;5:e15697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3009734</ArticleId><ArticleId IdType="pubmed">21203469</ArticleId></ArticleIdList></Reference><Reference><Citation>Head B.P., Hu Y., Finley J.C., Saldana M.D., Bonds J.A., Miyanohara A., Niesman I.R., Ali S.S., Murray F., Insel P.A. Neuron-targeted caveolin-1 protein enhances signaling and promotes arborization of primary neurons. J.&#xa0;Biol. Chem. 2011;286:33310&#x2013;33321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3190943</ArticleId><ArticleId IdType="pubmed">21799010</ArticleId></ArticleIdList></Reference><Reference><Citation>Head B.P., Patel P.M., Patel H., Roth M. Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord. US patent 8969077B2. 2012 filed November 7, 2011, and granted May 10, 2012.</Citation></Reference><Reference><Citation>Heinz S., Romanoski C.E., Benner C., Glass C.K. The selection and function of cell type-specific enhancers. Nat. Rev. Mol. Cell Biol. 2015;16:144&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4517609</ArticleId><ArticleId IdType="pubmed">25650801</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoerndli F.J., Toigo M., Schild A., G&#xf6;tz J., Day P.J. Reference genes identified in SH-SY5Y cells using custom-made gene arrays with validation by quantitative polymerase chain reaction. Anal. Biochem. 2004;335:30&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">15519568</ArticleId></ArticleIdList></Reference><Reference><Citation>Hruz T., Wyss M., Docquier M., Pfaffl M.W., Masanetz S., Borghi L., Verbrugghe P., Kalaydjieva L., Bleuler S., Laule O. RefGenes: identification of reliable and condition specific reference genes for RT-qPCR data normalization. BMC Genomics. 2011;12:156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072958</ArticleId><ArticleId IdType="pubmed">21418615</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiau T., Conant D., Rossi N., Maures T., Waite K., Yang J., Joshi S., Kelso R., Holden K., Enzmann B.L. Inference of CRISPR edits from Sanger trace data. bioRxiv. 2018 doi: 10.1101/251082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/251082</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y.-F., Gulko B., Siepel A. Fast, scalable prediction of deleterious noncoding variants from functional and population genomic data. Nat. Genet. 2017;49:618&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5395419</ArticleId><ArticleId IdType="pubmed">28288115</ArticleId></ArticleIdList></Reference><Reference><Citation>Hujoel M.L.A., Gazal S., Hormozdiari F., van de Geijn B., Price A.L. Disease heritability enrichment of regulatory elements is concentrated in elements with ancient sequence age and conserved function across species. Am. J. Hum. Genet. 2019;104:611&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6451699</ArticleId><ArticleId IdType="pubmed">30905396</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M., Furumichi M., Tanabe M., Sato Y., Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017;45(D1):D353&#x2013;D361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5210567</ArticleId><ArticleId IdType="pubmed">27899662</ArticleId></ArticleIdList></Reference><Reference><Citation>Karczewski K.J., Francioli L.C., Tiao G., Cummings B.B., Alf&#xf6;ldi J., Wang Q., Collins R.L., Laricchia K.M., Ganna A., Birnbaum D.P. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581:434&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7334197</ArticleId><ArticleId IdType="pubmed">32461654</ArticleId></ArticleIdList></Reference><Reference><Citation>Karnuta J.M., Scacheri P.C. Enhancers: bridging the gap between gene control and human disease. Hum. Mol. Genet. 2018;27(R2):R219&#x2013;R227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6061867</ArticleId><ArticleId IdType="pubmed">29726898</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch F., Fenouil R., Gut M., Cauchy P., Albert T.K., Zacarias-Cabeza J., Spicuglia S., de la Chapelle A.L., Heidemann M., Hintermair C. Transcription initiation platforms and GTF recruitment at tissue-specific enhancers and promoters. Nat. Struct. Mol. Biol. 2011;18:956&#x2013;963.</Citation><ArticleIdList><ArticleId IdType="pubmed">21765417</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowia&#x144;ski P., Lietzau G., Czuba E., Wa&#x15b;kow M., Steliga A., Mory&#x15b; J. BDNF: A Key Factor with Multipotent Impact on Brain Signaling and Synaptic Plasticity. Cell Mol. Neurobiol. 2018;38:579&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5835061</ArticleId><ArticleId IdType="pubmed">28623429</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S., Emond M.J., Bamshad M.J., Barnes K.C., Rieder M.J., Nickerson D.A., Christiani D.C., Wurfel M.M., Lin X., NHLBI GO Exome Sequencing Project&#x2014;ESP Lung Project Team Optimal unified approach for rare-variant association testing with application to small-sample case-control whole-exome sequencing studies. Am. J. Hum. Genet. 2012;91:224&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3415556</ArticleId><ArticleId IdType="pubmed">22863193</ArticleId></ArticleIdList></Reference><Reference><Citation>Lek M., Karczewski K.J., Minikel E.V., Samocha K.E., Banks E., Fennell T., O&#x2019;Donnell-Luria A.H., Ware J.S., Hill A.J., Cummings B.B., Exome Aggregation Consortium Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5018207</ArticleId><ArticleId IdType="pubmed">27535533</ArticleId></ArticleIdList></Reference><Reference><Citation>Levo M., Zalckvar E., Sharon E., Dantas Machado A.C., Kalma Y., Lotam-Pompan M., Weinberger A., Yakhini Z., Rohs R., Segal E. Unraveling determinants of transcription factor binding outside the core binding site. Genome Res. 2015;25:1018&#x2013;1029.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4484385</ArticleId><ArticleId IdType="pubmed">25762553</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Li X., Zhang S., Snyder M. Gene-environment interaction in the era of precision medicine. Cell. 2019;177:38&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">30901546</ArticleId></ArticleIdList></Reference><Reference><Citation>Longair M.H., Baker D.A., Armstrong J.D. Simple Neurite Tracer: open source software for reconstruction, visualization and analysis of neuronal processes. Bioinformatics. 2011;27:2453&#x2013;2454.</Citation><ArticleIdList><ArticleId IdType="pubmed">21727141</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandyam C.D., Schilling J.M., Cui W., Egawa J., Niesman I.R., Kellerhals S.E., Staples M.C., Busija A.R., Risbrough V.B., Posadas E. Neuron-targeted caveolin-1 improves molecular signaling, plasticity, and behavior dependent on the hippocampus in adult and aged mice. Biol. Psychiatry. 2017;81:101&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4826329</ArticleId><ArticleId IdType="pubmed">26592463</ArticleId></ArticleIdList></Reference><Reference><Citation>McCall M.N., McMurray H.R., Land H., Almudevar A. On non-detects in qPCR data. Bioinformatics. 2014;30:2310&#x2013;2316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4133581</ArticleId><ArticleId IdType="pubmed">24764462</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutoh T., Sobue G., Hamano T., Kuriyama M., Hirayama M., Yamamoto M., Mitsuma T. Decreased phosphorylation levels of TrkB neurotrophin receptor in the spinal cords from patients with amyotrophic lateral sclerosis. Neurochem Res. 2000;25:239&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">10786708</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen N.T.T., Contreras-Moreira B., Castro-Mondragon J.A., Santana-Garcia W., Ossio R., Robles-Espinoza C.D&gt;, Bahin M., Collombet S., Vincens P., Thieffry D. RSAT 2018: regulatory sequence analysis tools 20th anniversary. Nucleic. Acids Res. 2018;46:W209&#x2013;W214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6030903</ArticleId><ArticleId IdType="pubmed">29722874</ArticleId></ArticleIdList></Reference><Reference><Citation>Pallares L.F. Searching for solutions to the missing heritability problem. eLife. 2019;8:e53018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6892610</ArticleId><ArticleId IdType="pubmed">31799931</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennacchio L.A., Bickmore W., Dean A., Nobrega M.A., Bejerano G. Enhancers: five essential questions. Nat. Rev. Genet. 2013;14:288&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4445073</ArticleId><ArticleId IdType="pubmed">23503198</ArticleId></ArticleIdList></Reference><Reference><Citation>Project MinE ALS Sequencing Consortium Project MinE: study design and pilot analyses of a large-scale whole-genome sequencing study in amyotrophic lateral sclerosis. Eur. J. Hum. Genet. 2018;26:1537&#x2013;1546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6138692</ArticleId><ArticleId IdType="pubmed">29955173</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A.R., Bender D., Maller J., Sklar P., de Bakker P.I.W., Daly M.J., Sham P.C. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 2007;81:559&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>Raczy C., Petrovski R., Saunders C.T., Chorny I., Kruglyak S., Margulies E.H., Chuang H.-Y., K&#xe4;llberg M., Kumar S.A., Liao A. Isaac: ultra-fast whole-genome secondary analysis on Illumina sequencing platforms. Bioinformatics. 2013;29:2041&#x2013;2043.</Citation><ArticleIdList><ArticleId IdType="pubmed">23736529</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhie S.K., Schreiner S., Witt H., Armoskus C., Lay F.D., Camarena A., Spitsyna V.N., Guo Y., Berman B.P., Evgrafov O.V. Using 3D epigenomic maps of primary olfactory neuronal cells from living individuals to understand gene regulation. Sci. Adv. 2018;4:eaav8550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6292713</ArticleId><ArticleId IdType="pubmed">30555922</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan M., Heverin M., McLaughlin R.L., Hardiman O. Lifetime risk and heritability of amyotrophic lateral sclerosis. JAMA Neurol. 2019;76:1367&#x2013;1374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6646974</ArticleId><ArticleId IdType="pubmed">31329211</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawada A., Wang S., Jian M., Leem J., Wackerbarth J., Egawa J., Schilling J.M., Platoshyn O., Zemljic-Harpf A., Roth D.M. Neuron-targeted caveolin-1 improves neuromuscular function and extends survival in SOD1G93A mice. FASEB J. 2019;33:7545&#x2013;7554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6529340</ArticleId><ArticleId IdType="pubmed">30894019</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmick M., Bastiaens P.I.H. The interdependence of membrane shape and cellular signal processing. Cell. 2014;156:1132&#x2013;1138.</Citation><ArticleIdList><ArticleId IdType="pubmed">24630717</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 2008;3:1101&#x2013;1108.</Citation><ArticleIdList><ArticleId IdType="pubmed">18546601</ArticleId></ArticleIdList></Reference><Reference><Citation>Taliun D., Harris D.N., Kessler M.D., Carlson J., Szpiech Z.A., Torres R., Taliun S.A.G., Corvelo A., Gogarten S.M., Kang H.M. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. bioRxiv. 2019 doi: 10.1101/563866. Published online March 6, 2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/563866</ArticleId></ArticleIdList></Reference><Reference><Citation>Tooze S.A., Schiavo G. Liaisons dangereuses: autophagy, neuronal survival and neurodegeneration. Curr. Opin. Neurobiol. 2008;18:504&#x2013;515.</Citation><ArticleIdList><ArticleId IdType="pubmed">18840524</ArticleId></ArticleIdList></Reference><Reference><Citation>Trabjerg B.B., Garton F.C., van Rheenen W., Fang F., Henderson R.D., Mortensen P.B., Agerbo E., Wray N.R. ALS in Danish registries: heritability and links to psychiatric and cardiovascular disorders. Neurol. Genet. 2020;6:e398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7073454</ArticleId><ArticleId IdType="pubmed">32211514</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner B.J., Murray S.S., Piccenna L.G., Lopes E.C., Kilpatrick T.J., Cheema S.S. Effect of p75 neurotrophin receptor antagonist on disease progression in transgenic amyotrophic lateral sclerosis mice. J. Neurosci. Res. 2004;78:193&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">15378612</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W., Shatunov A., Dekker A.M., McLaughlin R.L., Diekstra F.P., Pulit S.L., van der Spek R.A., V&#xf5;sa U., de Jong S., Robinson M.R., PARALS Registry. SLALOM Group. SLAP Registry. FALS Sequencing Consortium. SLAGEN Consortium. NNIPPS Study Group Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat. Genet. 2016;48:1043&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5556360</ArticleId><ArticleId IdType="pubmed">27455348</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward L.D., Kellis M. Evidence of abundant purifying selection in humans for recently acquired regulatory functions. Science. 2012;337:1675&#x2013;1678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4104271</ArticleId><ArticleId IdType="pubmed">22956687</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>